Anti-TNFRSF13C / BAFFR / CD268 Reference Antibody (such as ianalumab) is a key tool in immunology research and development, particularly in studying the BAFF signaling pathway involved in B-cell survival and maturation. This antibody facilitates the detection, localization, and isolation of B cells expressing the BAFFR receptor on their surface, which is crucial for investigating autoimmune disorders such as rheumatoid arthritis, autoimmune hemolytic anemia, and systemic lupus erythematosus (SLE).

Additionally, it is used in the development of targeted therapies against the BAFF pathway to reduce abnormal or overactive B cells, potentially controlling chronic inflammation and autoimmune responses. It holds promise for future treatments of chronic autoimmune diseases, offering a targeted modulation of the immune system with potentially fewer broad immunosuppressive effects. While the therapeutic counterpart (ianalumab) is administered intravenously for conditions like SLE, Sjögren’s syndrome, and other B-cell-mediated disorders, this reference antibody supports preclinical research and validation.